DocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular Care

NEW YORK–(BUSINESS WIRE)–DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced an expanded partnership with SHL Telemedicine (NASDAQ: SHLT) to integrate the SmartHeart® portable 12-lead ECG device across DocGo mobile health care units. This expanded collaboration, initially launched in the New York-New Jersey area, will now bring advanced cardiovascular diagnostics to patients’ homes and underserved communities in additional markets across the country.

“We are proud to extend our partnership with DocGo to provide accessible, high-quality cardiovascular diagnostics that help patients achieve better health outcomes while addressing the nation’s pressing need for equitable healthcare access”

Post this

According to the Journal of the American College of Cardiology, 46% of U.S. counties do not have any cardiologists¹, highlighting the urgent need for accessible cardiovascular care. SHL Telemedicine’s SmartHeart®, a cutting-edge ECG device enabling high-quality 12-lead ECG performance anytime and anywhere, enhances patient care by eliminating the need for traditional clinic visits for essential cardiovascular screenings. With cardiologist-reviewed results available promptly, this innovation improves patient outcomes, especially for those in areas lacking cardiologists or access to healthcare facilities. This helps to eliminate many of the traditional obstacles that have discouraged people from engaging with cardiovascular healthcare providers.

“This partnership transforms homes and mobile health units into cutting-edge diagnostic hubs, empowering patients with convenient, high-quality care wherever they are,” said Lee Bienstock, CEO of DocGo. “Incorporating SmartHeart® into home visits helps reduce barriers to cardiovascular care, while enabling early intervention and preventing costly emergency room visits.”

The partnership expansion also represents DocGo’s continued innovation in delivering scalable, patient-centric healthcare solutions that help improve outcomes while lowering overall costs.

“We are proud to extend our partnership with DocGo to provide accessible, high-quality cardiovascular diagnostics that help patients achieve better health outcomes while addressing the nation’s pressing need for equitable healthcare access,” said David Arnon, CEO of SHL Telemedicine.

The first phase of this partnership expansion will focus on California, where DocGo is actively addressing healthcare access challenges in underserved areas. By equipping mobile health vehicles with SmartHeart® technology, DocGo will provide critical cardiovascular diagnostics to rural communities and healthcare deserts.

About DocGo

DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo’s proprietary technology and relationships with a dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient’s home or workplace. Together with DocGo’s integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com. To get an inside look on how the proactive healthcare revolution is helping transform healthcare by reducing costs, increasing efficiency and improving outcomes, visit www.proactivecarenow.com.

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users who use SmartHeart for personal use and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP: 78423T200). For more information, please visit our website at www.shl-telemedicine.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the Company’s plans, strategies, outcomes, and prospects, both business and financial, including the Company’s expanded partnership with SHL Telemedicine, the expected benefits of such partnership and the expected benefits of SmartHeart® devices. These statements are based on the beliefs and assumptions of the Company’s management. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions, outcomes, results or expectations. Accordingly, you should not place undue reliance on such statements. All statements other than statements of historical fact are forward-looking. In some cases, these statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “might,” “will,” “should,” “could,” “can,” “would,” “design,” “potential,” “seeks,” “plans,” “scheduled,” “anticipates,” “intends” or the negative of these terms or similar expressions. Forward-looking statements are inherently subject to substantial risks, uncertainties and assumptions, many of which are beyond the Company’s control, and which may cause the Company’s actual results or outcomes, or the timing of results or outcomes, to differ materially from those contained in the Company’s forward-looking statements, including, but not limited to the following: the Company’s ability to successfully implement its business strategy, including with respect to its partnership with SHL Telemedicine and the use of SmartHeart® devices; the Company’s reliance on and ability to maintain its contractual relationships with its healthcare provider partners and clients; the Company’s ability to compete effectively in a highly competitive industry; the Company’s ability to maintain existing contracts; the Company’s reliance on government contracts; the Company’s ability to effectively manage its growth; the Company’s financial performance and future prospects; the Company’s ability to deliver on its business strategies or models, plans and goals; the Company’s ability to expand geographically; the Company’s competitive position and opportunities, including its ability to realize the benefits from its operating model; and other risk factors included in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements made in this press release are based on events or circumstances as of the date on which the statements are made. The Company undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as and to the extent required by law.

¹ https://www.forbes.com/sites/brucelee/2024/08/19/cardiology-deserts-46-of-us-counties-do-not-have-any-cardiologists/